Sickle cell anemia (SCA) is an inherited red blood disorder. The kidneys are among the most commonly affected organ systems in SCA. The Food and Drug Administration (FDA) has approved empagliflozin as a treatment to reduce the decline of kidney function in those with kidney disease. The proposed research study aims to determine whether empagliflozin can prevent the progression of kidney dysfunction in patients with sickle cell anemia (SCA) who are at high risk of developing advanced chronic kidney disease (CKD).
Age range
18 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Efficacy of empagliflozin - urine biomarker: Adenosine
Timeframe: From enrollment to the end of treatment at 48 weeks
Efficacy of empagliflozin - urine biomarker: Nephrin
Timeframe: From enrollment to the end of treatment at 48 weeks
Efficacy of empagliflozin - urine biomarker: Kidney injury molecule-1
Timeframe: From enrollment to the end of treatment at 48 weeks
Efficacy of empagliflozin R2* Cortical Oxygenation on kidney fMRI
Timeframe: From enrollment to the end of treatment at 48 weeks